chir-99021 and Parkinson-Disease

Leucine rich repeat kinase 2 (LRRK2) is an enigmatic enzyme and a relevant target for Parkinson's disease (PD). However, despite the significant amount of research done in the past decade, the precise function of LRRK2 remains largely unknown. Moreover, the therapeutic potential of its inhibitors is in its infancy with the first clinical trial having just started. In the present work, the molecular mechanism of LRRK2 in the control of neurogenesis or gliogenesis was investigated. We designed and synthesized novel benzothiazole-based LRRK2 inhibitors and showed that they can modulate the Wnt/β-catenin signaling pathway. Furthermore, compounds

Topics: Animals; Benzothiazoles; Cells, Cultured; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Neurogenesis; Oligodendroglia; Parkinson Disease; Protein Kinase Inhibitors; Wnt Signaling Pathway